Join
Live feed
·
PRReleasevia Quantisnow
Gain Therapeutics Inc. logo

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

ByQuantisnow·Wall Street's wire, on your screen.
GANX· Gain Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GANX (Gain Therapeutics Inc.) and more on Quantisnow.